

# Grace Kong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2794461/publications.pdf>

Version: 2024-02-01

29  
papers

1,912  
citations

361413

20  
h-index

501196

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

2300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of <sup>177</sup> Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 218-225.	5.0	22
2	Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response” <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 218, 767-780.	2.2	15
3	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of <sup>177</sup> Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5027-5027.	1.6	1
4	Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on <sup>68</sup> Ga-DOTATATE PET/CT and <sup>18</sup> F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 204-216.	6.4	30
5	Radionuclide imaging of NENs. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 207-215.	1.4	0
6	Early Outcomes of Surgery for Carcinoid Heart Disease. <i>Heart Lung and Circulation</i> , 2020, 29, 742-747.	0.4	12
7	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup> Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 857-865.	5.0	191
8	Technical Note: Rapid multiexponential curve fitting algorithm for voxel-based targeted radionuclide dosimetry. <i>Medical Physics</i> , 2020, 47, 4332-4339.	3.0	7
9	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [ <sup>177</sup> Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2322-2327.	6.4	101
10	PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). <i>Endocrine-Related Cancer</i> , 2020, 27, R67-R77.	3.1	79
11	Peptide Receptor Radiotherapy: Current Approaches and Future Directions. <i>Current Treatment Options in Oncology</i> , 2019, 20, 77.	3.0	40
12	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for <sup>177</sup> Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2019, 2, 670-676.	5.4	134
13	The Role of <sup>68</sup> Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5091-5099.	3.6	23
14	Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. <i>Journal of Clinical Medicine</i> , 2019, 8, 1455.	2.4	4
15	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1902-1910.	6.4	37
16	<sup>64</sup> Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 777-785.	5.0	98
17	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 718-727.	6.4	17
18	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. <i>JMIR Research Protocols</i> , 2019, 8, e14361.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 262-277.	6.4	97
20	Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 1597.	7.1	68
21	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3278-3287.	3.6	125
22	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 476-489.	6.4	42
23	Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 87-96.	0.6	102
24	68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. <i>Cancer Imaging</i> , 2016, 16, 22.	2.8	135
25	Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 176-185.	6.4	91
26	High management impact of Ga <sup>68</sup> DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 40-47.	1.8	217
27	The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 50-56.	6.4	119
28	177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1869-1875.	6.4	60
29	High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 527-533.	1.0	42